In DMD model mice that received the full-length human DMD replacement therapy, plasma titin was suggested to be more sensitive marker than plasma CK (25) In recent years, several active clinical trials for novel treatments for DMD such as exon-skipping therapy and micro-dystrophin therapy, have been conducted with some of these approaches already approved in certain countries (26). This evidence concerns the gene TTN and Duchenne muscular dystrophy.